This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Health stocks came off the holiday weekend with modest gains, though Onyx Pharmaceuticals (ONXX) was left choking on a clinical trial news.

Onyx and partner Bayer AG said Tuesday that they halted a late-stage trial of their drug Nexavar in lung cancer patients after an independent monitoring board concluded that the study had no chance to succeed. Onyx also said on a conference call that it is unable to forecast a profit for 2008. Shares shed $10.69, or 24%, to $34.25.

Elsewhere, Medivation (MDVN - Get Report) said Tuesday its 2007 loss more than doubled due to an increase in operating expenses, though the results were better than Wall Street expectations. The biopharmaceutical company reported a loss of $31.7 million, or $1.14 a share, widened from a loss of $15.4 million, or 63 cents a share, in 2006. Analysts anticipated a loss of $1.17 a share.

Shares of Medivation rose 76 cents, or 4.4%, to $17.86 on less-than-average volume.

Onyx and Medivation are both components of the Nasdaq biotechnology index, which was up 1.65, or 0.2%, to 797.12.

Elsewhere, UBS analyst Annabel Samimy downgraded Pharmasset (VRUS) to neutral from buy, but raised her price target to $23 from $17 a share. She believes that the value of the company's hepatitis B and C drugs, clevudine and R7128, is now reflected in the stock price. Shares of Pharmasset fell $1.53, or 7.1%, at $19.97.

Among upgrades, WR Hambrecht raised Watson Pharmaceuticals (WPI) to buy from hold and BMO Capital Markets upgraded UnitedHealth (UNH - Get Report) to outperform from market perform. Watson tacked on 45 cents, or 1.7%, to 28.40, and UnitedHealth shares added 55 cents, or 1.1%, at 48.28.

Also, Thomas Weisel upgraded Cephalon (CEPH) to overweight from market-weight with a $77 price target. Shares advanced 97 cents, or 1.6%, at $61.59.

Separately, Cephalon said the Food and Drug Administration accepted its new drug application for Treanda for injection to treat of patients with indolent B-cell non-Hodgkin's lymphoma who've progressed during or following standard treatment. An FDA decision is expected by Oct. 31.

And last, on the falling end, Given Imaging (GIVN) said late Monday that the FDA issued it a "not substantially equivalent" letter that indicated the agency will not approve the company's PillCam Colon imaging device.

Given Imaging, which makes tiny diagnostic cameras, said the development isn't likely to affect 2008 revenue. The company said it is evaluating its options to bring PillCam Colon to the U.S. market as quickly as possible.

Shares fell $2.15, or 13.9%, to $13.30.

Given Imaging is 18.3% held by Israeli company Elron Electronic Industries (ELRN). Elron was trading down $1.17, or 10.9%, at $9.53.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
WPI $85.73 0.00%
GIVN $0.00 0.00%
ELRN $0.10 0.00%
MDVN $58.01 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs